News | February 23, 2022
Vicore advances on new chemical entity from VP03 program
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Revenue of $1.67 billion represents 8% reported growth; and up 9% on a core(basis.
Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
John served as General Manager for Catalent Pharma Solutions in St. Petersburg, Florida
The SureSTART consumables portfolio is designed for higher performance requirements, while meeting customer budgets
New expanded indication provides patients suffering from earlier stages of heart failure access to the CardioMEMS HF System, a small implantable sensor that can flag early warning signs of worsening heart failure
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
Prior to joining Biosion, Edwards was Vice President of Corporate Strategy and operations at Ionis Pharmaceuticals.
Subscribe To Our Newsletter & Stay Updated
